Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

Guaranteed issue underwriting continues to dominate the voluntary benefits market, according to a new report from Eastbridge Consulting Group. The "Underwriting Practices of Voluntary Carriers" ...

Capital Group, one of the world's largest and most experienced active investment managers, issued its 2025 capital market assumptions (CMAs), which represent the company's long-term expectations for ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Alnylam’s pipeline is built on small interfering RNA (siRNA), synthetic molecules that silence specific mRNAs. After nearly 15 years of investment in the field, Alnylam is now nearing the moment ...

“This is changing the practice of medicine,” says Kevin Fitzgerald, chief scientific officer of RNAi pioneer Alnylam Pharmaceuticals ... the potential to silence essentially any gene ...

potentially bringing it into competition with biotech heavyweights such as Alnylam, something that Mortazavi focused on during his long time at the helm of Silence Therapeutics. The company has ...

The HDBuzz team caught up with editor emeritus and Huntington's disease specialist, Prof Ed Wild to hear his thoughts on what ...

Pushkal Garg; Chief Medical Officer, Executive Vice President - Development and Medical Affairs; Alnylam Pharmaceuticals Inc Jeffrey Poulton; Chief Financial Officer, Executive Vice President; Alnylam ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post to the agency’s website. Published first on ...